Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693562 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Evaluate MEDI4736
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,022
- Enrollment target
NCT01693562 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 1,022 participants.
The verdict
NCT01693562, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,022 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in participants with advanced solid tumors followed by an expansion phase in participants with advanced solid tumors. An exploration cohort has been added to determine the safety using every 4 weeks (Q4W) dosing.
Interventions
- DRUG MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,022 participants |
| Start Date | 2012-09-05 |
| Est. Completion | 2020-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01693562
The ClinicalTrials.gov registry entry for NCT01693562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,022 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI4736 is the first listed.
NCT01693562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01693562 about?
NCT01693562 is a clinical study titled "A Phase 1/2 Study to Evaluate MEDI4736". This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in participants with advanced solid tumors followed by an expansion phase in participants with advanced solid tumors. An exploration cohort has been added to determine the safety using every 4 week...
What is the current status of trial NCT01693562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,022 participants. The study started on 2012-09-05. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT01693562?
The interventions under investigation include: MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT01693562?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.